Aratana Enters Animal Health Industry With $20 Million In Funding

Posted: January 7, 2011, 5:30 p.m., EDT



Published:

Aratana Therapeutics of Kansas City, Kan., reported today that it has received $20 million in Series A financing, led by MPM Capital and Avalon Ventures.

The newly-formed company will focus on developing pharmaceutical therapies for the animal health industry.

“At Aratana, we will be focused on taking advancements from the human biopharmaceutical industry and applying them in new ways to treat and care for animals,” said David Rosen, DVM, president and founder of Aratana Therapeutics.

Specifically, Aratana will fund, develop and manage the clinical trials and development activities necessary to achieve regulatory approval, according to the Kansas Bioscience Authority, which awarded $1 million to the start-up company. The goal is to partner these products to animal health companies “that have a meaningful presence in the relevant sector of the animal health market.”

Aratana will welcome Linda Rhodes, VMD, Ph.D., as CEO in February. Previously, Dr. Rhodes was founder and vice president of clinical development at AlcheraBio, an entrepreneurial contract research organization focused on helping major animal health companies develop new drugs.

“My entire career has been devoted to developing therapies for animals, and I am looking forward to continuing that work in this exciting, venture-capital model at Aratana,” she said.

Aratana’s board of directors will include Rhodes; Steven St. Peter, MD, managing director at MPM Capital; Jay Lichter, managing director at Avalon Ventures; and Ron Meeusen, founder of Cultivian Ventures.

<Home>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Purdue’s Trustees Give Green Light on $60 Million Ag, Life Sciences Facility

The Board of Trustees also took actions to advance an equine center in Shelbyville, Ind.

FTC Open to Wider Veterinary Drug Market

Veterinarians face growing competition from retail outlets, and the trend is likely to continue for better or worse.

K-State Unveils Test for New Dog Flu Strain

The Veterinary Diagnostic Laboratory uses sequencing to identify H3N2 and help in the search for a vaccine.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module